U.S. Air Force School of Aerospace Medicine, Wright-Patterson AFB, OH.
Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX.
Spine (Phila Pa 1976). 2017 Sep 15;42(18):1405-1411. doi: 10.1097/BRS.0000000000002133.
A population-based retrospective cohort study.
The aim of this study was to examine risk factors for long-term opioid use following lumbar spinal fusion surgery in a nationally representative cohort of commercially insured adults.
Opioid prescription rates for the management of low back pain have more than doubled in the US over the past decade. Although opioids are commonly used for the management of pain following lumbar spinal fusion surgery, to date, no large-scale nationally representative studies have examined the risk factors for long-term opioid use following such surgical intervention.
Using one of the nation's largest commercial insurance databases, we conducted a retrospective cohort study of 8377 adults, aged 21 to 63 years, who underwent lumbar spinal fusion surgery between January 1, 2009, and December 31, 2012. Long-term opioid use was defined as ≥365 days of filled opioid prescriptions in the 24 months following lumbar fusion. Multivariable logistic regression was used to calculate adjusted odds ratios (ORs) and 95% confidence intervals for the risk of long-term opioid use following lumbar fusion.
After adjusting for covariates, the following factors were associated with an increased risk of long-term opioid use following surgery: duration of opioid use in the year before lumbar surgery [Referent (0 days); Quartile 1 (1-22 days) OR = 2.27, 95% CI = 1.48-3.49; Quartile 2 (23-72 days): OR = 5.94, 95% CI = 4.00-8.83; Quartile 3: (73-250 days) OR = 25.31, 95% CI = 17.26-37.10; Quartile 4 (≥250 days) OR = 219.95, 95% CI = 148.53-325.71)], refusion surgery (OR = 1.32, 95% CI = 1.02-1.72), and diagnosis of depression (OR = 1.43, 95% CI = 1.18-1.74). Receipt of anterior fusion was associated with a modest decrease in the risk of long-term opioid use (OR = 0.79, 95% CI = 0.63-0.99).
These findings may provide clinically relevant information to physicians, patients, and their families regarding the risk factors for opioid dependence following lumbar fusion surgery.
基于人群的回顾性队列研究。
本研究旨在检查在全国范围内具有代表性的商业保险成年人队列中,腰椎融合术后长期使用阿片类药物的风险因素。
在过去十年中,美国管理下腰痛的阿片类药物处方率增加了一倍以上。尽管阿片类药物常用于腰椎融合术后疼痛的管理,但迄今为止,尚无大规模的全国代表性研究检查此类手术干预后长期使用阿片类药物的风险因素。
我们使用美国最大的商业保险数据库之一,对 8377 名年龄在 21 至 63 岁之间的成年人进行了回顾性队列研究,这些成年人在 2009 年 1 月 1 日至 2012 年 12 月 31 日期间接受了腰椎融合术。长期阿片类药物使用定义为腰椎融合后 24 个月内至少有 365 天的阿片类药物处方。多变量逻辑回归用于计算腰椎融合术后长期使用阿片类药物的风险调整比值比(OR)和 95%置信区间。
在调整了协变量后,以下因素与手术后长期使用阿片类药物的风险增加相关:腰椎手术前一年阿片类药物使用的持续时间[参考(0 天);第 1 季度(1-22 天)OR=2.27,95%CI=1.48-3.49;第 2 季度(23-72 天):OR=5.94,95%CI=4.00-8.83;第 3 季度:(73-250 天)OR=25.31,95%CI=17.26-37.10;第 4 季度(≥250 天)OR=219.95,95%CI=148.53-325.71)]、再融合手术(OR=1.32,95%CI=1.02-1.72)和抑郁症诊断(OR=1.43,95%CI=1.18-1.74)。接受前路融合术与长期阿片类药物使用风险降低有关(OR=0.79,95%CI=0.63-0.99)。
这些发现可能为腰椎融合术后阿片类药物依赖的风险因素向医生、患者及其家属提供临床相关信息。
3 级。